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A B S T R A C T
Background
Airway oedema and mucus plugging are the predominant pathological features in infants with acute viral bronchiolitis. Nebulised
hypertonic saline solution may reduce these pathological changes and decrease airway obstruction.
Objectives
To assess the effects of nebulised hypertonic (≥ 3%) saline solution in infants with acute viral bronchiolitis.
Search methods
We searched CENTRAL 2013, Issue 4, OLDMEDLINE (1951 to 1965), MEDLINE (1966 to April week 4, 2013), EMBASE (1974
to May 2013), LILACS (1985 to May 2013) and Web of Science (1955 to May 2013).
Selection criteria
Randomised controlled trials (RCTs) and quasi-RCTs using nebulised hypertonic saline alone or in conjunction with bronchodilators
as an active intervention and nebulised 0.9% saline as a comparator in infants up to 24 months of age with acute bronchiolitis.
Data collection and analysis
Two review authors independently performed study selection, data extraction and assessment of risk of bias in included studies. We
conducted meta-analyses using the Cochrane statistical package RevMan 5.2. We used the random-effects model for meta-analyses.
We used mean difference (MD) and risk ratio (RR) as effect size metrics.
Main results
We included 11 trials involving 1090 infants with mild to moderate acute viral bronchiolitis (500 inpatients, five trials; 65 outpatients,
one trial; and 525 emergency department patients, four trials). All but one of the included trials were of high quality with a low risk
of bias. A total of 560 patients received hypertonic saline (3% saline n = 503; 5% saline n = 57). Patients treated with nebulised 3%
saline had a significantly shorter mean length of hospital stay compared to those treated with nebulised 0.9% saline (MD -1.15 days,
95% confidence interval (CI) -1.49 to -0.82, P < 0.00001). The hypertonic saline group also had a significantly lower post-inhalation
clinical score than the 0.9% saline group in the first three days of treatment (day 1: MD -0.88, 95% CI -1.36 to -0.39, P = 0.0004; day
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2: MD -1.32, 95% CI -2.00 to -0.64, P = 0.001; day 3: MD -1.51, 95% CI -1.88 to -1.14, P < 0.00001). The effects of improving
clinical score were observed in both outpatients and inpatients. Four emergency department-based trials did not show any significant
short-term effects (30 to 120 minutes) of up to three doses of nebulised 3% saline in improving clinical score and oxygen saturation.
No significant adverse events related to hypertonic saline inhalation were reported.
Authors’ conclusions
Current evidence suggests nebulised 3% saline may significantly reduce the length of hospital stay among infants hospitalised with
non-severe acute viral bronchiolitis and improve the clinical severity score in both outpatient and inpatient populations.
P L A I N L A N G U A G E S U M M A R Y
Hypertonic saline solution administered via nebuliser for acute bronchiolitis in infants
Acute viral bronchiolitis is the most common lower respiratory tract infection in infants up to two years old. Currently there is
no effective treatment so standard treatment remains supportive care. Airway oedema (abnormal accumulation of fluid) and mucus
plugging can cause wheezing and difficulty breathing in these patients. Nebulised hypertonic saline may be a beneficial treatment to
manage acute bronchiolitis because it can improve airway hygiene. This review was conducted to assess the effects of hypertonic (≥
3%) saline solution administered via a nebuliser in infants with acute bronchiolitis, compared with nebulised normal (0.9%) saline.
The establishment of a therapeutic role for hypertonic saline solution may provide a cheap and effective therapy for these patients.
We included 11 randomised trials involving 1090 infants with mild to moderate bronchiolitis. All but one of the 11 trials are considered
as high-quality studies with low risk of error (i.e. bias) in their conclusions. Meta-analysis suggests that nebulised hypertonic saline
could lead to a reduction of 1.2 days in the mean length of hospital stay among infants hospitalised for non-severe acute bronchiolitis
and improve the clinical severity score in both outpatient and inpatient populations. No significant short-term effects (at 30 to 120
minutes) of one to three doses of nebulised hypertonic saline were observed among emergency department patients. However, more
trials are needed to address this question. There were no significant adverse effects noted with the use of nebulised hypertonic saline
when administered along with bronchodilators.
Given the clinically relevant benefit and good safety profile, nebulised hypertonic saline used in conjunction with bronchodilators
should be considered an effective and safe treatment for infants with mild to moderate acute viral bronchiolitis.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Nebulised hypertonic saline compared with nebulised 0.9% saline for acute bronchiolitis in infants
Patient or population: infants up to 24 months of age with acute bronchiolitis
Settings: outpatient, emergency department or inpatient
Intervention: nebulised hypertonic saline (≥ 3%)
Comparison: nebulised 0.9% saline
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Nebulised 0.9% saline Nebulised hypertonic
saline
Length of hospital stay
(days)
The mean length of hos-
pital stay ranged across
control groups from
3.5 to 7.4 days
The mean length of hospi-
tal stay in the intervention
groups was on average
1.15 days shorter
(95% CI -1.49 to -0.82)
500
(6 inpatient trials)
⊕⊕⊕⊕
high
Clinical severity score
(post-treatment) at day
1
The clinical score of
Wang 1992 in which each
of 4 symptoms and signs
(respiratory rate, wheez-
ing, retraction and general
condition) was graded on
a scale of 0 to 3, with
increased severity receiv-
ing a higher score
The mean clinical severity
score ranged across con-
trol groups from
3.97 to 8.8
The mean clinical severity
score in the intervention
groups was on average
0.88 lower
(95% CI -1.36 to -0.39)
640
(7 trials: 1 outpatient, 1
emergency department, 5
inpatients)
⊕⊕⊕⊕
high
Given the small number
of participants, the small
number of inhalations (up
to three doses) and short
monitoring time (up to
120 minutes post-inhala-
tion), further large RCTs
with multiple doses of
hypertonic saline over a
longer period of time are
still needed for evaluating
the effect of nebulised hy-
pertonic saline in improv-
ing clinical score among
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infants with acute bron-
chiolitis seen in emer-
gency departments
Clinical severity score
(post-treatment) at day
2
The clinical score of
Wang 1992 as described
above
The mean clinical severity
score ranged across con-
trol groups from
3.8 to 8.2
The mean clinical severity
score in the intervention
groups was on average
1.32 lower
(95% CI -2.00 to -0.64)
636
(7 trials: 1 outpatient, 1
emergency department, 5
inpatients)
⊕⊕⊕⊕
high
The same comments as
described above
Clinical severity score
(post-treatment) at day
3
The clinical score of
Wang 1992 as described
above
The mean clinical severity
score ranged across con-
trol groups from
2.9 to 7.6
The mean clinical severity
score in the intervention
groups was on average
1.51 lower
(95% CI -1.88 to -1.14)
439
(6 trials: 1 outpatient, 5
inpatients)
⊕⊕⊕⊕
high
The same comments as
described above
Rate of hospitalisation
Duration of follow-up:
5 days for outpatient
trial; up to 120 min-
utes for emergency de-
partment trial
25 per 189 16 per 191 RR 0.63
(0.37 to 1.07)
380
(4 trials: 1 outpatient,
3 emergency department
trials)
⊕⊕⊕©
moderate
Low statistical power due
to small sample sizes
may have contributed to
the negative result. Fur-
ther large RCTs are re-
quired to evaluate the ef-
ficacy of nebulised hy-
pertonic saline in prevent-
ing hospitalisation among
infants with acute viral
bronchiolitis seen in out-
patient settings or emer-
gency departments
Rate of readmission
Duration of follow-up: up
to 1 week after discharge.
22 per 153 32 per 213 RR 1.05
(0.62 to 1.76)
366
(3 emergency department
trials)
⊕⊕⊕©
moderate
Further large RCTs are re-
quired to evaluate the effi-
cacy of nebulised hyper-
tonic saline in reducing
the rate of readmission
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among infants with acute
viral bronchiolitis seen in
inpatient settings, outpa-
tient settings or emer-
gency departments
Adverse events See comment See comment Not estimable 1090 (560 received hy-
pertonic saline)
(11 trials)
⊕⊕⊕⊕
high
No significant adverse
events related to hy-
pertonic saline inhalation
were observed in any
of the 11 trials. No
patients were withdrawn
from the trial by the med-
ical staff because of ad-
verse events or clinical
deterioration
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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B A C K G R O U N D
Description of the condition
Acute bronchiolitis is the most frequent lower respiratory tract in-
fection in infants (Klassen 1997a). Most cases are viral in origin,
with the leading cause being the respiratory syncytial virus (RSV).
Other less common pathogens include parainfluenza viruses, ade-
novirus, influenza A and B, rhinovirus, human metapneumovirus
and Mycoplasma pneumoniae (M. pneumoniae) (Garcia-Garcia
2006; Henderson 1979; Jacques 2006; Rose 1987; Shay 2001).
Virtually all infants are infected by RSV by the age of two years,
around 40% to 50% develop involvement of the lower respiratory
tract and 1% to 2% develop severe disease leading to hospitalisa-
tion (Meissner 2003; Rakshi 1994; Shay 1999). Over the last few
decades, an increasing trend in the rate of hospitalisation of chil-
dren with bronchiolitis has been observed in the USA and Canada
(Langley 2003; Njoo 2001; Shay 1999).
In acute bronchiolitis, the principal pathological findings include
a peribronchial infiltrate of inflammatory cells, mucosal and sub-
mucosal oedema, necrosis and desquamation of ciliated epithe-
lial cells, proliferation of cuboidal cells and excess mucus secre-
tion (Panitch 1993; Wohl 1978). The combination of airway wall
swelling, sloughing of necrotic debris, increased mucus produc-
tion and impaired secretion clearance eventually leads to airway
obstruction, gas trapping, atelectasis and impaired gas exchange.
The diagnosis of acute bronchiolitis is usually based on clinical
grounds. Despite the definition of bronchiolitis differing from
country to country, it is generally accepted that acute bronchiolitis
refers to the first episode of acutewheezing in children less than two
years of age, starting as a viral upper respiratory infection (coryza,
cough or fever) (Panitch 1993). These criteria for diagnosis of acute
bronchiolitis have also been widely used in clinical trials (Bertrand
2001; Klassen 1997b; Schuh 1992; Wainwright 2003; Zhang
2003). Direct fluorescent antibody tests, enzyme immunoassay
techniques and cultures of the nasopharyngeal aspirate may be
used to identify the causative pathogen.
Description of the intervention
The standard treatment for acute bronchiolitis remains supportive
care and includes ensuring adequate oxygen exchange, fluid intake
and feeding of the infant (Panitch 2003; Wohl 2003). There is
a lack of convincing evidence for any other therapy. As airway
oedema and mucus plugging are the predominant pathological
features in acute bronchiolitis, any therapeutic modality which
can reduce these pathological changes and improve the clearance
of airway secretions may be beneficial.
Epinephrine has a theoretical effect on acute bronchiolitis because
it contains alpha adrenergic properties which lead to vasoconstric-
tion and reduction of airway oedema (Wohl 1978). However, a
recent Cochrane Review showed that nebulised epinephrine for
acute bronchiolitis results in a modest short-term improvement in
outpatients, but not among inpatients (Hartling 2011). Inhaled
recombinant deoxyribonuclease (rhDNase), amucolytic agent, has
also been tested in hospitalised infants with acute bronchiolitis
(Nasr 2001). This drug is thought to exert its major effect by en-
hancing airway secretion clearance. However, no significant effect
was observed on clinical severity scores or on the length of hospi-
tal stay (Enriquez 2012). Another widely used approach is chest
physiotherapy, which is thought to assist infants by enhancing the
clearance of secretions and reducing ventilatory effort. However,
the current evidence concludes that chest physiotherapy (vibration
and percussion or passive expiratory techniques) does not reduce
the length of hospital stay, oxygen requirements or improve the
severity of the disease, respiratory parameters in hospitalised in-
fants with acute bronchiolitis (Roqué i Figuls 2012).
Hypertonic saline has been recently introduced as a treatment for
infants with acute bronchiolitis. Most randomised trials demon-
strate that nebulised 3% saline may significantly reduce the length
of hospital stay and improve the clinical severity score in infants
with acute viral bronchiolitis (Luo 2010;Mandelberg 2003; Sarrell
2002; Tal 2006).
How the intervention might work
Hypertonic saline solution has been shown to increase mucocil-
iary clearance in normal individuals and in patients with asthma,
bronchiectasis, cystic fibrosis and sinonasal diseases (Daviskas
1996; Kellett 2005; Shoseyov 1998; Wark 2009). Such bene-
fits would also be expected in infants with acute bronchiolitis
(Mandelberg 2010). The postulated mechanisms of benefit are
as follows: 1) hypertonic saline induces an osmotic flow of water
into the mucus layer, rehydrating the airway surface liquid and
improving mucus clearance (Mandelberg 2010; Robinson 1997);
2) hypertonic saline breaks the ionic bonds within the mucus gel,
thereby reducing the degree of cross-linking and entanglements
and lowering the viscosity and elasticity of the mucus secretion
(Ziment 1978); 3) hypertonic saline stimulates cilial beat via the
release of prostaglandin E2 (Assouline 1977). Moreover, by ab-
sorbing water from the mucosa and submucosa, hypertonic saline
solution can theoretically reduce oedema of the airway wall in
infants with acute bronchiolitis (Mandelberg 2003; Mandelberg
2010; Sarrell 2002). Hypertonic saline inhalation can also cause
sputum induction and cough, which can help to clear the spu-
tum outside of the bronchi and thus improve airway obstruction
(Mandelberg 2003). The above mentioned theoretical benefits
provide the rationale for the treatment of acute bronchiolitis with
nebulised hypertonic saline solution.
Why it is important to do this review
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The hypothesis of this review is that nebulised hypertonic saline
solution is beneficial in the management of acute bronchiolitis as
assessed by clinically relevant outcomes, both in inpatients and
outpatients. The establishment of a therapeutic role for hypertonic
saline solution in acute bronchiolitis has relevant clinical impli-
cations. This modality may provide a cheap and effective therapy
for children with acute bronchiolitis.
O B J E C T I V E S
To assess the effects of nebulised hypertonic (≥ 3%) saline solution
in infants with acute viral bronchiolitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) and quasi-
RCTs (where there is alternate allocation to treatment and con-
trol groups) in this review. We excluded studies which included
patients who had had recurrent wheezing or were intubated and
ventilated, and studies which assessed pulmonary function alone.
Types of participants
Infants up to 24 months of age with the diagnosis of acute bron-
chiolitis. Acute bronchiolitis was defined as the first episode of
acute wheezing associated with clinical evidence of a viral infection
(cough, coryza or fever). Confirmation of viral aetiology was not
necessary for study inclusion. We included studies of inpatients,
emergency department patients or outpatients.
Types of interventions
1. Nebulised hypertonic saline alone versus nebulised 0.9%
saline
2. Nebulised hypertonic saline plus bronchodilator versus
nebulised 0.9% saline
3. Nebulised hypertonic saline plus bronchodilator versus
nebulised 0.9% saline plus same bronchodilator
4. Nebulised hypertonic saline alone or plus bronchodilator
versus no intervention
Given the very limited number of studies that were identified
initially, we added the comparison of nebulised hypertonic saline
alone versus nebulised 0.9% saline. Hypertonic saline was defined
as a concentration of saline greater than or equal to 3%.
Types of outcome measures
Primary outcomes
1. Length of hospital stay or time taken to be ready for
discharge (inpatients)
2. Rate of hospitalisation (outpatients or emergency
department patients)
Secondary outcomes
1. Clinical severity scores
2. Rate of readmission to hospital
3. Haemoglobin saturation (oximetry)
4. Respiratory rate
5. Heart rate
6. Time for the resolution of symptoms/signs
7. Duration of in-hospital oxygen supplementation
8. Results of pulmonary function tests
9. Radiological findings
10. Adverse events (tachycardia, hypertension, pallor, tremor,
nausea, vomiting, diarrhea and acute urinary retention)
Search methods for identification of studies
Electronic searches
For this 2013 update we searched the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL) 2013, Issue 4, part of The
Cochrane Library, www.thecochranelibrary.com (accessed 8 May
2013), which contains the Cochrane Acute Respiratory Infections
Group Specialised Register, MEDLINE (May 2010 to April week
4, 2013), EMBASE (June 2010 to April 2013) and LILACS (June
2010 to May 2013). We broadened our search to include two fur-
ther databases and searched CINAHL (1981 to May 2013) and
Web of Science (1955 to May 2013). See Appendix 1 for details
of the previous search.
We used the following search strategy to search MEDLINE and
CENTRAL. As there were so few search results we used no filter to
identify randomised trials in MEDLINE. We adapted the search
terms to search EMBASE (Appendix 2), LILACS (Appendix 3),
CINAHL (Appendix 4) and Web of Science (Appendix 5).
MEDLINE (OVID)
1 exp Bronchiolitis/
2 (bronchiolit* or wheez*).tw.
3 respiratory syncytial viruses/ or respiratory syncytial virus, hu-
man/
4 Respiratory Syncytial Virus Infections/
5 (respiratory syncytial virus* or rsv).tw.
6 parainfluenza virus 1, human/ or parainfluenza virus 3, human/
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7 Parainfluenza Virus 2, Human/
8 Respirovirus Infections/
9 Adenovirus Infections, Human/
10 Rhinovirus/
11 Influenza, Human/
12 exp influenzavirus a/ or exp influenzavirus b/
13 (parainfluenza* or respirovirus* or adenovirus* or rhinovirus*
or influenza*).tw.
14 or/1-13
15 Saline Solution, Hypertonic/
16 (hypertonic adj3 (saline or solution*)).tw.
17 Sodium Chloride/
18 (sodium chloride or saline).tw.
19 or/15-18
20 exp “Nebulizers and Vaporizers”/
21 (nebuli* or vapor* or vapour* or atomi*).tw.
22 Administration, Inhalation/
23 inhal*.tw.
24 Aerosols/
25 aerosol*.tw.
26 or/20-25
27 14 and 19 and 26
There were no language or publication restrictions.
Data collection and analysis
Selection of studies
Two review authors (LZ, RAM) independently assessed the titles
and abstracts of all studies identified by the searches. We obtained
the full articles when they appeared to meet the inclusion criteria
or there were insufficient data in the title and abstract to make
a clear decision for their inclusion. We excluded articles that did
not meet the inclusion criteria. We noted the reasons for their ex-
clusion (see Characteristics of excluded studies table). We resolved
any disagreements between the two review authors about study
inclusion by discussion.
Data extraction and management
One review author (LZ) extracted study details from the in-
cluded trials using a standardised data extraction form. These
were checked by another review author (RAM). We resolved any
disagreements by discussion. We entered the extracted data into
RevMan 2012. We extracted the following data.
1. Study characteristics: publication status, year, country of
study and setting.
2. Methods: method of allocation, blinding of participants
and assessment of outcome, exclusion of participants after
randomisation, proportion of follow-up losses and intention-to-
treat analysis.
3. Participants: sample size, age, sex, and inclusion and
exclusion criteria.
4. Intervention: concentration of saline, volume of saline,
interval of administration, treatment duration and co-
interventions.
5. Control: nebulised 0.9% saline or nil.
6. Outcomes: primary and secondary outcomes as described
previously. For continuous outcomes, we extracted sample size,
mean and standard deviation for each group. For dichotomous
outcomes, we extracted sample size and number of events for
each group.
When the trial recruited multiple groups, we combined them
into the hypertonic saline group and the normal saline group. In
the trial of Al-Ansari 2010, we combined 5% saline group and
3% saline group into the hypertonic saline group. In the trial
of Anil 2010, we combined four groups (3% saline mixed with
epinephrine, 3% saline mixed with salbutamol, 0.9% saline mixed
with epinephrine and 0.9% saline mixed with salbutamol) into
the hypertonic saline group and the normal saline group. In the
trial of Ipek 2011, we combined four groups (3% saline plus salbu-
tamol, 3% saline alone, 0.9% saline plus salbutamol and 0.9%
saline alone) into the hypertonic saline group and the normal saline
group.
Assessment of risk of bias in included studies
Two review authors (LZ, RAM) independently assessed the po-
tential risk of bias in included studies according to The Cochrane
Collaboration’s ’Risk of bias’ tool (Higgins 2011). Assessment re-
sults are summarised in the ’Risk of bias’ tables.
Measures of treatment effect
We synthesised dichotomous data using risk ratios (RR) and 95%
confidence intervals (CI) as the effect measures. We used the mean
difference (MD) and 95% CI as the metrics of effect size for
continuous outcomes.
Dealing with missing data
We contacted three principal investigators (Kuzik 2007; Luo
2010; Mandelberg 2003) for additional data on clinical score and
methodological aspects. All three trial authors responded and pro-
vided the requested data.
Assessment of heterogeneity
We assessed heterogeneity in results between studies using the
Cochrane Q test (P < 0.1 considered significant) and the I2 statis-
tic. The I2 statistic ranges from 0% to 100% and measures the
degree of inconsistency across studies, with values of 25%, 50%
and 75% corresponding to low, moderate and high heterogeneity,
respectively (Higgins 2003).
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Assessment of reporting biases
Reporting biases, especially publication bias, may be expected to
occur in the majority of systematic reviews. Unfortunately there
is no reliable method to detect publication bias. To minimise the
potential reporting biases, we used no language restrictions for the
literature searches. We contacted experts and searched the cur-
rently available trial registration databases for additional published
or unpublished trials.
Data synthesis
We performed the meta-analyses using the Cochrane statistical
package RevMan 5.2 (RevMan 2012). We used the random-ef-
fectsmodel formeta-analyses.We conducted random effectsmeta-
regression using Stata version 11.0 (Stata-Corp, College Station,
TX, USA). Whenever possible, we used intention-to-treat (ITT)
analysis data.
Subgroup analysis and investigation of heterogeneity
Weperformed pre-planned subgroup analysis according to patient
status (outpatient, emergency department patient and inpatient).
The severity of disease and treatment regime (concentration of
saline, volume, interval of inhalation, drug delivery and duration
of treatment) may also contribute to heterogeneity in effect sizes
across studies.We conducted post hoc random-effectsmeta-regres-
sion using Restricted Maximum Likelihood Estimation (REML)
to explore these possible causes of heterogeneity between studies.
R E S U L T S
Description of studies
Results of the search
The initial search of electronic databases in 2007 retrieved a to-
tal of 261 citations (Zhang 2008). After reviewing the titles and
abstracts, we identified seven papers as being potentially relevant,
which we reviewed in full text. Four trials met all the criteria for
study selection and were included in the initial review.
The update search in 2010 (Zhang 2011) retrieved 39 citations
and three additional trials were identified and included in the
updated review.
This 2013 updated search retrieved 158 citations from the elec-
tronic databases. From them we identified four new trials. There-
fore, a total of 11 trials were included in this updated review. See
the Characteristics of included studies table.
Included studies
All 11 studies were randomised, double-blind, parallel-group, con-
trolled trials. One study was a multi-centre trial involving one hos-
pital in the United Arab Emirates and two hospitals in Canada
(Kuzik 2007). Three trials were conducted by the same group of
investigators in Israel (Mandelberg 2003; Sarrell 2002; Tal 2006)
and two trials were conducted by one group of investigators in
China (Luo 2010; Luo 2011). The remaining five studies were
conducted in Turkey (Anil 2010; Ipek 2011), Canada (Grewal
2009), Qatar (Al-Ansari 2010) and Italy (Giudice 2012).
Participants
One trial recruited outpatient participants (Sarrell 2002), four tri-
als recruited emergency department participants (Al-Ansari 2010;
Anil 2010; Grewal 2009; Ipek 2011) and six trials recruited
inpatients (Giudice 2012; Kuzik 2007; Luo 2010; Luo 2011;
Mandelberg 2003; Tal 2006). The mean age of participants varied
from 2.6 to 12.5 months (range: 9 days to 24 months). The crite-
ria for diagnosis of viral bronchiolitis were clearly defined by seven
trials (Al-Ansari 2010; Anil 2010; Giudice 2012; Grewal 2009;
Ipek 2011; Kuzik 2007; Luo 2011). Virological investigation was
available in all trials except two (Anil 2010; Ipek 2011) and the
positive rate for respiratory syncytial virus (RSV) varied from 42%
to 88%. Patients with a previous wheezing episode were excluded
in all 11 trials. Patients hospitalised with severe bronchiolitis (re-
quiring mechanical ventilation or intensive care, or oxygen satura-
tion < 85% on room air) were also excluded in all inpatient trials.
Interventions
The concentrationof hypertonic salinewas defined at 3% in all but
one trial (Al-Ansari 2010), in which two concentrations (3% and
5%) were used. Treatment regimens of nebulised hypertonic saline
(volume, interval of administration, addition of bronchodilator
and treatment duration) varied across studies, especially emer-
gency department-based trials (Table 1). Oxygen or compressed
air-driven jet nebulisers were used for drug deliveries in all but one
trial (Tal 2006), in which ultrasonic nebulisers were utilised.
Outcome measures
All six inpatient trials (Giudice 2012; Kuzik 2007; Luo 2010;
Luo 2011; Mandelberg 2003; Tal 2006) used length of hospital
stay as the primary outcome measure. The same clinical severity
score was used by five trials (Giudice 2012; Luo 2010; Luo 2011;
Mandelberg 2003; Tal 2006) as the secondary outcome measure.
This clinical score was initially described by Wang (Wang 1992),
grading respiratory rate, wheezing, retraction and general condi-
tion from 0 to 3, with increased severity receiving a higher score.
For outpatients or emergency department participants (Al-Ansari
2010; Anil 2010; Grewal 2009; Ipek 2011; Sarrell 2002), rate of
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hospitalisation, rate of readmission and/or clinical severity score
were used as the outcome measures.
Other outcome measures used in the trials were haemoglobin
saturation (oximetry) (Al-Ansari 2010; Anil 2010; Grewal 2009;
Ipek 2011; Mandelberg 2003), pulse rate (Anil 2010; Ipek 2011;
Mandelberg 2003; Sarrell 2002), respiratory rate (Ipek 2011) and
time for the resolution of symptoms/signs (Luo 2010; Luo 2011).
The radiological assessment score initially described by Nasr 2001
was used by two trials (Mandelberg 2003; Sarrell 2002).
Side effects associated with inhaled therapies were reported in all
10 trials.
Excluded studies
We excluded four studies from the review. The reasons for exclu-
sion are summarised in the Characteristics of excluded studies ta-
ble.
Risk of bias in included studies
All but one (Ipek 2011) of the 11 included trials were of high
methodological quality with low risk of bias. Summary assessment
of six key domains is described below and presented in Figure 1.
Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Four trials (Grewal 2009; Mandelberg 2003; Tal 2006; Sarrell
2002) used an online randomiser and six (Al-Ansari 2010; Anil
2010; Giudice 2012; Kuzik 2007; Luo 2010; Luo 2011) used a
computer-based random number program to generate the ran-
dom sequence. All but four trials (Al-Ansari 2010; Giudice 2012;
Ipek 2011; Luo 2011) used sequentially numbered drug contain-
ers of identical appearance for allocation concealment. Two trials
(Al-Ansari 2010; Luo 2011) used sequentially numbered, opaque,
sealed envelopes for allocation concealment. In the trial of Giudice
2012, study solutions were prepared by the local hospital phar-
macy, but themethodof allocation concealmentwas not described.
The trial of Ipek 2011 assigned patients to treatment groups ac-
cording to the consecutive order of their admission to the emer-
gency department.
Blinding
In all but one (Ipek 2011) of the 11 included trials, participants,
care providers and investigators were blinded to group assignment.
The trial of Ipek 2011 was stated to be double-blinded, but no
details were provided.
Incomplete outcome data
The number of participants with missing data was small in all 11
trials. Thus, incomplete outcome data may not be a source of bias
in this review. Intention-to-treat (ITT) analysis was used by three
trials (Grewal 2009; Kuzik 2007; Sarrell 2002).
Selective reporting
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There was no evidence of selective reporting of outcomes in the
included studies.
Other potential sources of bias
No other potential sources of bias were observed in the included
trials.
Effects of interventions
See: Summary of findings for the main comparison
Eleven RCTs involving 1090 infants with mild to moderate acute
viral bronchiolitis (500 inpatients, 65 outpatients and 525 emer-
gency department patients) compared nebulised hypertonic saline
to nebulised 0.9% saline.
Primary outcome
1. Length of hospital stay or time taken to be ready for
discharge (inpatients)
All six inpatient trials (Giudice 2012; Kuzik 2007; Luo 2010;
Luo 2011; Mandelberg 2003; Tal 2006) demonstrated a benefit
of nebulised 3% saline in reducing the duration of hospitalisation.
The pooled results show that infants treated with nebulised 3%
saline had a statistically significant shorter mean length of hospital
stay compared to those treated with nebulised 0.9% saline, with
a pooled mean difference (MD) of -1.15 days (95% confidence
interval (CI) -1.49 to -0.82, P < 0.00001) (Analysis 1.1) (Figure
2). This represents a 22.7% reduction from the mean length of
hospital stay in the 0.9% saline group. There was no significant
heterogeneity in results between studies (P = 0.21; I2 statistic =
30%).
Figure 2. Hypertonic saline versus 0.9% saline: length of hospital stay (days)
2. Rate of hospitalisation (outpatients or emergency
department patients)
One outpatient trial (Sarrell 2002) and three emergency depart-
ment trials (Anil 2010; Grewal 2009; Ipek 2011) with a com-
bined total of 380 participants assessed the efficacy of nebulised
3% saline in reducing the risk of hospitalisation. There was no
significant reduction in rate of hospitalisation. The pooled risk
ratio (RR) was 0.63 (95% CI 0.37 to 1.07, P = 0.09) (Analysis
1.2) (Figure 3). There was no significant heterogeneity between
studies (P = 0.99; I2 statistic = 0%).
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Figure 3. Hypertonic saline versus 0.9% saline: rate of hospitalisation.
Secondary outcomes
1. Clinical severity scores
One outpatient (Sarrell 2002), one emergency (Al-Ansari 2010)
and five inpatient trials (Giudice 2012; Luo 2010; Luo 2011;
Mandelberg 2003; Tal 2006) used theWang 1992 clinical severity
score as an outcome. All seven trials compared the post-inhalation
clinical scores between infants treated with nebulised hypertonic
saline and those treated with nebulised 0.9% saline on the first
three days of treatment. The baseline clinical scores were compa-
rable between the two groups in all seven trials.
On the first day of treatment, one outpatient trial (n = 65) (Sarrell
2002) showed that the 3% saline group had a statistically signif-
icant lower post-inhalation clinical score compared to the 0.9%
saline group, with a MD of -1.28 (95% CI -1.92 to -0.64, P <
0.0001) (Analysis 1.3.1). Five inpatient trials (Giudice 2012; Luo
2010; Luo 2011; Mandelberg 2003; Tal 2006) with a total of 404
patients also demonstrated significant benefits of hypertonic saline
in reducing clinical score (pooled MD -0.99, 95% CI -1.48 to -
0.50, P < 0.00001) (Analysis 1.3.3), in spite of significant hetero-
geneity between studies (P = 0.02; I2 statistic = 67%). In contrast,
one emergency department trial (Al-Ansari 2010) with 171 pa-
tients did not show the superiority of hypertonic saline over nor-
mal saline in reducing clinical score (MD -0.09, 95% CI -0.51 to
0.33, P = 0.68). The pooled results from all seven trials showed
a significantly lower post-inhalation clinical score favouring treat-
ment with nebulised hypertonic saline over nebulised 0.9% saline
on the first day of treatment, with a pooled MD of -0.88 (95%
CI -1.36 to -0.39, P = 0.0004) (Analysis 1.3) (Figure 4). This dif-
ference represents a 13.6% reduction from the mean clinical score
in the 0.9% saline group on the first day of treatment. There was
significant heterogeneity in results between studies (P = 0.0001; I
2 statistic = 78%).
Figure 4. Hypertonic saline versus 0.9% saline: clinical severity score (post-treatment) at day 1
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On the second day of treatment, one outpatient trial (n = 65)
(Sarrell 2002) showed a lower post-inhalation clinical score in the
3% saline group compared to the 0.9% saline group, with aMDof
-2.0 (95% CI -2.93 to -1.07, P < 0.0001) (Analysis 1.4.1). A sig-
nificant difference between the treatment and control groups was
also observed among 400 inpatients (Giudice 2012; Luo 2010;
Luo 2011; Mandelberg 2003; Tal 2006), with a pooled MD of
-1.45 favouring 3% saline group (95% CI -2.06 to -0.85, P <
0.00001) (Analysis 1.4.3). There was significant heterogeneity be-
tween inpatient trials (P = 0.0008; I2 statistic = 79%). One emer-
gency department trial (n = 171) (Al-Ansari 2010) failed to show
significant benefits of hypertonic saline in reducing clinical score
(MD -0.27, 95% CI -0.63 to 0.09, P = 0.14) (Analysis 1.4.2).
The meta-analysis of seven trials demonstrated the superiority of
nebulised 3% saline over 0.9% saline in reducing the post-inhala-
tion clinical score on the second day of treatment, with a pooled
MD of -1.32 (95% CI -2.00 to -0.64, P < 0.0001) (Analysis 1.4)
(Figure 5). This difference represents a 23.0% reduction from the
mean clinical score in the 0.9% saline group for the second day
of treatment. Significant heterogeneity was found between studies
(P < 0.00001; I2 statistic = 89%).
Figure 5. Hypertonic saline versus 0.9% saline: clinical severity score (post-treatment) at day 2
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On the third day of treatment, one outpatient trial (n = 65) (Sarrell
2002) showed a lower post-inhalation clinical score in the 3%
saline group compared to the 0.9% saline group, with a MD of -
2.64 (95% CI -3.85 to -1.43, P < 0.0001) (Analysis 1.5.1). The
five inpatient trials (n = 374) (Giudice 2012; Luo 2010; Luo 2011;
Mandelberg 2003; Tal 2006) also showed a lower post-inhalation
clinical score in the 3% saline group (pooled MD -1.44, 95% CI
-1.78 to -1.10, P < 0.00001) (Analysis 1.5.2). Moderate hetero-
geneity was observed between inpatient trials (P = 0.08; I2 statistic
= 53%). The pooled results from these five trials demonstrated the
superiority of nebulised 3% saline over 0.9% saline in reducing the
post-inhalation clinical score on the third day of treatment (pooled
MD -1.51, 95% CI -1.88 to -1.14, P < 0.00001) (Analysis 1.5)
(Figure 6). This difference represents a 29.4% reduction from the
mean clinical score in the 0.9% saline group. There was significant
heterogeneity between studies (P = 0.04; I2 statistic = 58%).
Figure 6. Hypertonic saline versus 0.9% saline: clinical severity score (post-treatment) at day 3.
To explore the possible causes of heterogeneity across studies re-
garding the effect size of hypertonic saline on clinical score during
the first three days of treatment, we performed post hoc meta-
regression in which the effect estimate (mean difference of clinical
score) is predicated by one or more explanatory variables (poten-
tial effect modifiers or covariates). The small number of studies
allowed us to include only one relevant covariate in the model
which was the severity of bronchiolitis assessed by clinical score in
the 0.9% saline group. The meta-regression yielded a regression
coefficient of 0.05 (95% CI -0.15 to 0.25, P = 0.59), suggesting
that the severity of disease did not significantly influence the effect
size of hypertonic saline.
Three emergency department-based trials (Anil 2010; Grewal
2009; Ipek 2011) assessed short-term effects (30 to 120 minutes)
of up to three doses of nebulised 3% saline in improving clinical
score among infants with acute bronchiolitis. No significant ben-
efits were observed. There were also no significant effects on oxy-
gen saturation. Another emergency department trial (Al-Ansari
2010) showed a small but statistically significant lower clinical
score favouring treatment with nebulised 5% saline over nebulised
0.9% saline at 48 hours after randomisation (3.69 ± 1.09 versus
4.12 ± 1.11, P = 0.04) but not 24 hours after randomisation (3.75
± 1.27 versus 3.97 ± 1.40, P = 0.38). This trial did not find a
significant difference in clinical score at 24 hours and 48 hours
after randomisation between 3% saline and 0.9% saline.
2. Rate of readmission to hospital
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Three emergency department trials with a total of 366 partici-
pants (Al-Ansari 2010; Anil 2010; Grewal 2009) used rate of read-
mission as an outcome. The pooled results of these trials did not
demonstrate significant benefits of nebulised hypertonic saline in
reducing the risk of readmission (pooled RR 1.05, 95% CI 0.62
to 1.76, P = 0.87) (Analysis 1.6). There was no significant hetero-
geneity between studies (P = 0.81; I2 statistic = 0%).
3. Haemoglobin saturation (oximetry)
Five trials (Al-Ansari 2010; Anil 2010; Grewal 2009; Ipek 2011;
Mandelberg 2003) did not find a significant difference between
the hypertonic saline group and the 0.9% saline group in terms
of room air saturation of oxyhaemoglobin throughout the study
period.
4. Respiratory rate
One trial (Ipek 2011) reported no difference in respiratory rate
between the hypertonic saline group and the 0.9% saline group.
5. Heart rate
Four trials (Anil 2010; Ipek 2011;Mandelberg 2003; Sarrell 2002)
reported no difference in pulse rate between the hypertonic saline
group and the 0.9% saline group.
6. Time for the resolution of symptoms/signs
Two trials (Luo 2010; Luo 2011) reported the time for the res-
olution of wheezing, cough and pulmonary moist crackles. The
pooled results of two trials show that infants treated with nebu-
lised 3% saline had a shorter duration of respiratory symptoms
and sign compared to those treated with nebulised 0.9% saline,
with a pooled MD of -1.19 days (95% CI -1.54 to -0.84, P <
0.00001). There was significant heterogeneity in results between
studies (P = 0.0005; I2 statistic = 77.0%) (Analysis 1.7).
7. Duration of in-hospital oxygen supplementation
Not reported on.
8. Results of pulmonary function tests
Not reported on.
9. Radiological findings
In two trials (Mandelberg 2003; Sarrell 2002), the second chest
radiographwas obtained on the third days after hospital admission.
The pooled results of two trials did not show significant difference
in radiological score between the hypertonic saline group and the
0.9% saline group (pooled MD -0.08, 95% CI -0.90 to 0.75,
P = 0.85) (Analysis 1.8). There was no significant heterogeneity
between studies (P = 0.95; I2 statistic = 0%).
10. Adverse events (tachycardia, hypertension, pallor,
tremor, nausea, vomiting, diarrhea and acute urinary
retention)
No significant adverse events related to hypertonic saline inhala-
tion were observed in 11 trials. No patients were withdrawn from
the trial by the medical staff because of adverse events or clini-
cal deterioration. In the trial of Grewal 2009, three participants
presented with vomiting and one presented with diarrhea during
the study period. All four participants were enrolled in the 3%
saline group, but these symptoms might not be directly related to
nebulised hypertonic saline.
D I S C U S S I O N
Summary of main results
In this review, we defined the length of hospital stay as the primary
outcome to measure the efficacy of nebulised hypertonic saline
among inpatients with viral bronchiolitis. Despite differences in
inhalation mixture and delivery intervals across the studies, the
effect sizes of the treatment with 3% saline inhalation reported by
six independent studies (Giudice 2012; Kuzik 2007; Luo 2010;
Luo 2011; Mandelberg 2003; Tal 2006) were similar. That is,
there was approximately a one-day reduction in the duration of
hospitalisation. The pooled results from these five trials demon-
strate that nebulised 3% saline could produce a reduction of 1.15
days in the mean length of hospital stay. This represents a 22.7%
reduction from the mean length of hospitalisation in the normal
saline group. Given the high prevalence of viral bronchiolitis in
infants and the tremendous burden of this illness related to hos-
pitalisation, this reduction may be considered clinically relevant
and may potentially have a positive economic impact for both the
health system and the individual families.
The benefit of nebulised hypertonic saline in reducing the rate
of hospitalisation was assessed by four trials, one in outpatients
(Sarrell 2002) and three in emergency departments (Anil 2010;
Grewal 2009; Ipek 2011). The pooled results of these four tri-
als showed a 37% reduction in the risk of hospitalisation among
participants treated with 3% saline inhalation compared to those
treated with 0.9% saline inhalation. However, this reduction was
not statistically significant. Low statistical power due to small sam-
ple sizes may have contributed to this negative result. Further large
RCTs are required to evaluate the efficacy of nebulised hypertonic
saline in preventing hospitalisation among infants with acute viral
bronchiolitis seen at outpatient setting or emergency department.
The effects of hypertonic saline in reducing the rate of readmis-
sion were assessed by three emergency department trials (Al-Ansari
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2010; Anil 2010; Grewal 2009). The pooled results of three tri-
als did not demonstrate significant benefits of nebulised hyper-
tonic saline in reducing the risk of readmission. Caution should be
taken when interpreting the results of these three emergency de-
partment-based trials, given the small number of participants, the
small number of inhalations (up to three doses) and short mon-
itoring time (up to 120 minutes post-inhalation). Further large
RCTs withmultiple doses of hypertonic saline over a longer period
of time are still needed.
Clinical score is generally considered a relatively objective mea-
sure to assess the severity of illness. There are two clinical severity
scoring systemsmore commonly used by randomised trials involv-
ing infants with viral bronchiolitis. One is a Respiratory Distress
Assessment Instrument (RDAI) which assesses chest retractions
and auscultatory findings, and provides a score ranging from 0 to
17, with a higher score indicating more severe respiratory distress
(Lowell 1987). The other scoring system, initially described by
Wang, assesses respiratory rate, wheezing, retraction and general
condition, providing a score ranging from 0 to 12, with increased
severity receiving a higher score (Wang 1992). In this review, seven
trials utilised the clinical severity score system proposed by Wang
1992. The pooled results from these seven trials (one outpatient,
one emergency department and five inpatient) demonstrate a sta-
tistically significant lower mean post-inhalation score among in-
fants treated with 3% saline inhalation compared to those treated
with 0.9% saline inhalation in the first three days of treatment.
The magnitude of reduction in the severity score produced by 3%
saline inhalation may be considered clinically relevant because it
represents a reduction of up to 29% from the mean clinical score
in the 0.9% saline group. The benefits of nebulised hypertonic
saline in improving clinical score are observed in both outpatients
and inpatients, but not in emergency department patients over a
short period of time (30 to 120 minutes). There is significant het-
erogeneity across studies regarding effect size of hypertonic saline
on clinical score, especially between inpatient trials. We used post
hoc meta-regression to explore the possible causes of heterogene-
ity, however, the small number of studies allowed us to include
only the severity of bronchiolitis in the model and no significant
association was found between the severity of disease and the ef-
fect size of hypertonic saline. Despite the substantial heterogene-
ity, the size of effect but not the direction of effect varies across
studies, indicating that nebulised hypertonic saline is beneficial to
different degrees in improving clinical score among infants with
bronchiolitis. The potential effect modifiers have not been iden-
tified by this review, but they may include patient characteristics
and treatment regimens.
The potential side effects, principally acute bronchospasm, re-
main a concern with nebulised hypertonic saline. This review in-
cluded 560 infants receiving hypertonic saline (3% saline: n = 503;
5% saline: n = 57) in repeated doses and no significant adverse
events were reported. In nine trials (Al-Ansari 2010; Anil 2010;
Giudice 2012; Grewal 2009; Ipek 2011; Luo 2010; Mandelberg
2003; Sarrell 2002), the participants received hypertonic saline in-
halation in conjunction with bronchodilators. In one trial (Kuzik
2007), the study protocol defined the use of nebulised 3% saline
alone, but bronchodilators were added into the study solution in
60% of the treatments by attending physicians. Only 57 patients
in the trial of Luo 2011 and 30 patients in the trial of Ipek 2011
used 3% saline alone. Therefore, this review could not provide
convincing evidence regarding the safety of nebulised hypertonic
saline alone in infants with viral bronchiolitis. Given the possibil-
ity of acute bronchospasm induced by hypertonic saline in asth-
matics and the difficulty in distinguishing between asthma and
viral bronchiolitis in infants, it would seem reasonable to adminis-
ter hypertonic saline in conjunction with bronchodilators to avoid
any possible broncho-constrictive effect. The safety of nebulised
hypertonic saline, even in higher concentration (5% to 7%), has
recently been reported in patients with cystic fibrosis (Wark 2009)
and the authors attributed the good safety profile of the therapy to
the co-administration of hypertonic saline with bronchodilators.
In the trial of Al-Ansari 2010, no significant adverse events were
observed among 57 patients receiving nebulised 5% saline mixed
with 1.5 ml of epinephrine.
The inhalation therapy was administrated via jet nebulisers in all
but one trial (Tal 2006), in which ultrasonic nebulisers were used.
Theoretically, there are some differences in the physical proper-
ties of aerosols produced by jet nebulisers and ultrasonic nebu-
lisers, which may affect their therapeutical efficacies. On the one
hand, ultrasonic nebulisers induce sputum more efficiently than
jet nebulisers. On the other hand, jet nebulisers generate aerosols
with smaller aerodynamic mass median diameter which may more
easily reach smaller bronchi and bronchioles. This review could
not provide direct evidence regarding the impact of the physical
properties of aerosols generated by different types of nebulisers,
on the efficacy of inhaled hypertonic saline in infants with viral
bronchiolitis. However, at least one trial (Tal 2006) demonstrated
that both jet nebulisers and ultrasonic nebulisers are an efficient
method of delivery of hypertonic saline in these patients. Further
studies are required to compare the efficacy of nebulised hyper-
tonic saline delivered by different nebulisers in infants with viral
bronchiolitis.
The optimal treatment regime of nebulised hypertonic saline in
acute bronchiolitis remains unclear. One outpatient (Sarrell 2002)
and six inpatient trials (Giudice 2012; Kuzik 2007; Luo 2010; Luo
2011;Mandelberg 2003; Tal 2006) used multiple daily doses dur-
ing several days. All seven trials demonstrated significant effects
of hypertonic saline in reducing length of hospital stay, improving
clinical severity score or both. The most commonly used delivery
regime was three times daily at intervals of eight hours (Luo 2010;
Mandelberg 2003; Sarrell 2002; Tal 2006), and more frequent de-
liveries may not yield an additional benefit (Giudice 2012; Kuzik
2007). In contrast, three emergency department-based trials (Anil
2010; Grewal 2009; Ipek 2011) used small numbers of inhalations
during a short period (up to three inhalations within 120 min-
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utes) and all trials failed to show significant effects of hypertonic
saline in improving clinical score/oxygen saturation or in reducing
the risk of hospitalisation/readmission. These results may suggest
that nebulised hypertonic saline is effective for acute bronchiolitis
only when the treatment is given at multiple daily doses during a
reasonable period of time.
The concentration of nebulised hypertonic saline was 3% in all
but one trial (Al-Ansari 2010). In this emergency department trial,
two concentrations of hypertonic saline (3% and 5%) were used.
No superiority of 5% saline over 3% saline was observed in im-
proving clinical score at 24 hours and 48 hours after randomisa-
tion. However, further studies are still needed to establish the opti-
mal concentration and treatment regime of nebulised hypertonic
saline in infants with viral bronchiolitis.
Overall completeness and applicability of
evidence
This review included trials conducted in both high-income and
low-income countries and in different settings (inpatient, outpa-
tient and emergency department). Thus evidence derived from
this review may have a wide applicability. However, all 11 trials
included in this review recruited only infants with mild to moder-
ate bronchiolitis, so caution should be taken when extrapolating
the findings of this review to patients with more severe bronchioli-
tis, such as those requiring mechanical ventilation, intensive care
or having an oxygen saturation reading below 85% on room air.
The underlying airway pathological changes may differ between
severe and mild to moderate bronchiolitis, so different responses
to treatments with hypertonic saline may be expected in more se-
vere cases. Further trials are needed to assess the potential effects
of nebulised hypertonic saline in infants hospitalised with severe
acute bronchiolitis.
Quality of the evidence
All but one of the 11 included trials are of high methodological
quality with low risk of bias. However, some methodological con-
siderations should be mentioned. Firstly, eight trials (Al-Ansari
2010; Anil 2010; Giudice 2012; Ipek 2011; Luo 2010; Luo 2011
Mandelberg 2003; Tal 2006) did not use an intention-to-treat
analysis. This analysis strategy aims to maintain the unbiased
group comparison afforded by randomisation and to deal with
the problem of non-compliance and protocol deviation. As the
number of participants withdrawn after randomisation was small
in all these trials, the lack of application of an intention-to-treat
principle was unlikely to cause significant bias. Secondly, the sam-
ple size of this review was relatively small and the statistical power
of the study might be not sufficient for some outcome measures,
such as rate of hospitalisation and rate of readmission among out-
patients or emergency department patients. The small number of
studies included in the review also precludes an analytic approach
to heterogeneity across studies, however, this is a substantial het-
erogeneity only for clinical score but not other outcomes.
Potential biases in the review process
The strength of this review is that all but one of the included trials
have high quality and low risk of bias. Themain concern regarding
potential biases of this review is publication bias. We did not use
funnel plots or other analytic approaches to deal with the potential
publication bias, given the lack of reliable methods and relatively
small number of included studies.
Agreements and disagreements with other
studies or reviews
To the best of our knowledge, there is no other systematic review or
traditional narrative reviewwhich assesses the efficacy and safety of
nebulised hypertonic saline in infants with acute bronchiolitis. We
also failed to find observational studies that address this question.
This precludes a comparison of findings between this review and
other studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Nebulised 3% saline produces a 1.2 day reduction in the mean
length of hospital stay, compared to nebulised normal saline,
among infants hospitalised with non-severe acute bronchiolitis.
This therapy also significantly reduces clinical severity score among
outpatients and inpatients with mild to moderate bronchiolitis.
Given the clinically relevant benefit and good safety profile, nebu-
lised 3% saline used in conjunction with bronchodilators should
be considered an effective and safe treatment for infants with mild
to moderate acute viral bronchiolitis.
Implications for research
Further large randomised controlled trials, preferably multi-cen-
tred, are still required to evaluate the effectiveness of nebulised
hypertonic saline in infants with acute viral bronchiolitis, princi-
pally in infants who attend the emergency department and infants
hospitalised with severe acute bronchiolitis. The optimal delivery
intervals, duration of treatment and concentration of saline, and
the most effective delivery devices remain to be determined. The
mechanism of action of nebulised hypertonic saline in patients
with viral bronchiolitis also needs to be addressed in future studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Al-Ansari 2010
Methods Design: randomised, double-blind, parallel-group, controlled trial
Participants Setting: paediatric emergency facility in Qatar
Eligible: 87
Randomised: 115 HS group (5% saline: 57; 3% saline: 58); 56 NS group
Completed: 115 HS group; 56 NS group
Gender (male): 41.5%
Age: median age 3.1 months, range 9 days to 14.7 months
Inclusion criteria: Infants aged ≤ 18 months, with a prodromal history of viral upper
respiratory tract infection, followed by wheezing and/or crackles on auscultation and a
Wang bronchiolitis severity score of ≥ 4
Exclusion criteria: born at ≤ 34 weeks’ gestation, previous history of wheezing, steroid
use within 48 hours of presentation, obtundation and progressive respiratory failure
requiring intensive care unit (ICU) admission, history of apnoea within 24 hours before
presentation, oxygen saturation ≤ 85% on room air at the time of recruitment, history
of a diagnosis of chronic lung disease, congenital heart disease or immunodeficiency
Interventions Test groups:
Group 1: nebulised 5% hypertonic saline (5 ml) plus 1.5 ml of epinephrine
Group 2: nebulised 3% hypertonic saline (5 ml) plus 1.5 ml of epinephrine
Control groups: nebulised 0.9% normal saline (5 ml) plus 1.5 ml of epinephrine
The treatment was given every 4 hours, until the patient was ready for discharge. Nebu-
lised medications were delivered through a tight-fitting face mask by pressurised oxygen
with the flow meter set at 10 L/min
Outcomes Clinical severity score
Oxygen saturation
Length of stay
Need for ICU admission
Rate of readmission
Adverse events
Notes Virological identification not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based randomisation program
Allocation concealment (selection bias) Low risk Sequentially numbered and sealed en-
velopes
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Al-Ansari 2010 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised patients completed the trial
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Anil 2010
Methods Design: randomised, double-blind, parallel-group, controlled trial
Participants Setting: emergency department of a teaching hospital in Turkey
Eligible: 190
Randomised: 75 HS group; 111 NS group
Completed: 75 HS group;111 NS group
Gender (male): 64.5%
Age: mean age 9.5 months, range 1.5 to 24 months
Inclusion criteria: infants with diagnosis of bronchiolitis, which required a history of
upper respiratory infection and the presence of bilateral wheezing and/or crackles on
chest auscultation, plus clinical severity score between 1 and 9
Exclusion criteria: prematurity, any underlying disease (e.g. cystic fibrosis, bronchopul-
monary dysplasia and cardiac or renal disease), prior history of wheezing, atopic der-
matitis, allergic rhinitis or asthma, oxygen saturation (SaO2) < 85% on room air, CS
score > 9, obtunded consciousness, progressive respiratory failure requiring mechanical
ventilation, previous treatment with bronchodilators, and any steroid therapy within 2
weeks
Interventions Test groups:
Group 1: nebulised 3% hypertonic saline (4 ml) plus 1.5 mg of epinephrine
Group 2: nebulised 3% hypertonic saline (4 ml) plus 2.5 mg of salbutamol
Control groups:
Group 3: nebulised 0.9% normal saline (4 ml) plus 1.5 mg of epinephrine
Group 4: nebulised 0.9% normal saline (4 ml) plus 2.5 mg of salbutamol
Group 5: nebulised 0.9% normal saline (4 ml) alone
The study drug was administered at 0 and 30 min by Medic-Aid Sidestream nebuliser
(Medic-Aid Ltd., West Sussex, UK) using a face mask with continuous flow of 100%
oxygen at 6 L/min
Outcomes Clinical severity score
Oxygen saturation
Heart rate
Rate of hospitalisation
Rate of readmission
Adverse events
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Anil 2010 (Continued)
Notes Virological identification not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based randomisation program
Allocation concealment (selection bias) Low risk Sequentially numbered drug containers of
identical appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 withdrawals (2 protocol deviation, 2 par-
ents refused to participate in the study)
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Giudice 2012
Methods Design: randomised, double-blind, parallel-group, controlled trial
Participants Setting: Division of Pediatrics, Saint Mary Hospital in Pozzuoli, Naples, Italy
Eligible: 109
Randomised: 53 HS group; 56 NS group
Completed: 752 HS group; 54 NS group
Gender (male): 65.1%
Age: mean (SD): 4.8 (2.3) months HS group; 4.2 (1.6) months NS group
Inclusion criteria: children aged under 2 years with a diagnosis of bronchiolitis, defined
as the first episode of wheezing and clinical symptoms of a viral respiratory infection and
oxygen saturation < 94% in room air and significant respiratory distress
Exclusion criteria: pre-existing cardiac or pulmonary diseases, premature birth < 36weeks
of gestational age, previous diagnosis of asthma, initial oxygen saturation ≤ 85% or
respiratory distress severe enough to require resuscitation
Interventions Test group: nebulised 3.0% normal saline (? ml) plus 1.5 mg of epinephrine
Control group: nebulised 0.9% normal saline (? ml) plus 1.5 mg of epinephrine
Study solutions were given at intervals of 6 hours until discharge. Each treatment was
delivered by a nebuliser with continuous flow of oxygen at 6 L/min through a tight-
fitting face mask
Outcomes Length of hospital stay
Clinical score
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Giudice 2012 (Continued)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based randomisation program
Allocation concealment (selection bias) Unclear risk Study solutions were prepared by the local
hospital pharmacy, but the method of allo-
cation concealment was not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 withdrawals due to parent refusal to par-
ticipate in study (1 HS group; 2 NS group)
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Grewal 2009
Methods Design: randomised, double-blind, parallel-group, controlled trial
Participants Setting: emergency department of a children’s hospital in Canada
Eligible: 48
Randomised: 24 HS group; 24 NS group
Completed: 23 HS group; 23 NS group
Gender (male): 60.9%
Age: mean age 5 months, range 6 weeks to 12 months
Inclusion criteria: infants presenting with a first episode of wheezing and clinical symp-
toms of a viral respiratory infection, plus an initial oxygen saturation of 85% or more
but 96% or less, and Respiratory Distress Assessment Instrument (RDAI) score >= 4
Exclusion criteria: pre-existing cardiac or pulmonary disease, previous diagnosis of asthma
by a physician, any previous use of bronchodilators (except for treatment of the current
illness), severe disease requiring resuscitation room care, inability to take medication
using a nebuliser, inability to obtain informed consent secondary to a language barrier,
or no phone access for follow-up
Interventions Test group: nebulised 3% hypertonic saline (2.5 ml) plus 0.5 ml of 2.25% racaemic
epinephrine
Control group: nebulised 0.9% normal saline (2.5 ml) plus 0.5 ml of 2.25% racaemic
epinephrine
Both groups received inhalation solutions at 0 minutes. Each treatment was given by
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Grewal 2009 (Continued)
nebuliser with continuous flow of oxygen at 6 L/min. Two doses of the study drug were
available for each patient such that, if the physician felt that a second dose of racaemic
epinephrine was needed during the 120-minute study period, the patient received the
same drug combination again
Outcomes Clinical severity score
Oxygen saturation
Rate of hospitalisation
Rate of readmission
Adverse events
Notes RSV positive: 82.6% in HS group; 81.8% in NS group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Website randomisation scheme
Allocation concealment (selection bias) Low risk Sequentially numbered drug containers of
identical appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 withdrawal due to age > 12 months (HS)
, 1 inadvertently discharged prior to com-
pletion of study period (NS)
Intention-to-treat analysis used
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Ipek 2011
Methods Design: randomised, double-blind, parallel-group, controlled trial
Participants Setting: Paediatric Emergency Department of a training and research hospital in Turkey
Eligible: not stated
Randomised: 60 HS group; 60 NS group
Completed: 60 HS group; 60 NS group
Gender (male): 59.2%
Age: mean age 7.96 ± 3.91 months
Inclusion criteria: age < 2 years, a history of preceding viral upper respiratory infection
followed by wheezing and crackles on auscultation, and a Clinical Bronchiolitis Severity
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Ipek 2011 (Continued)
Score (CBSS) of 4 to 8 on admission
Exclusion criteria: infants with CBSS < 4 or > 8, oxygen saturation < 85% on room
air, chronic cardiac illness, premature birth, birth weight < 2500 G, history of recurrent
wheezing episodes, proven immune deficiency, severe neurological disease, age < 1month
or > 2 years, consolidation or atelectasis on a chest roentgenogram
Interventions Test groups:
Group 1: nebulised 3% hypertonic saline (4 ml) plus salbutamol 0.15 mg/kg
Group 2: nebulised 3% hypertonic saline (4 ml) alone
Control groups:
Group 1: nebulised 0.9% hypertonic saline (4 ml) plus salbutamol 0.15 mg/kg
Group 2: nebulised 0.9% hypertonic saline (4 ml) alone
The treatment was given every 20 min until 3 doses had been administered (0, 20 and
40th min). All inhaled therapies were delivered via a compressor nebuliser through a
facemask with continued flow of oxygen at 4e5 L/min (Minicompressor nebuliser, CN-
02WD, Ace-Tec Co., Ltd., Guangdong, China)
Outcomes Changes in clinical score after the treatment
Oxygen saturation
Respiratory rate
Heart beat rate
Corticosteroid need
Rate of hospitalisation
Adverse events
Notes Virological identification not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Patients were assigned to 1 of 4 groups ac-
cording to the consecutive order of their
admission to the short-stay unit
Allocation concealment (selection bias) High risk As stated above
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial was stated to be double-blind, but
no details were provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised patients completed the trial
Selective reporting (reporting bias) Low risk -
Other bias Unclear risk -
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Kuzik 2007
Methods Design: randomised, double-blind, parallel-group, controlled trial
Participants Setting: inpatient wards of 3 regional tertiary care hospitals, 1 in United Arab Emirates
and 2 in Canada
Eligible: not stated
Randomised: 47 HS group; 49 NS group
Completed: 45 HS group; 46 NS group
Gender (male): 59%
Age: mean age 4.7 months, range 10 days to 18 months
Inclusion criteria: infants with diagnosis of moderately severe bronchiolitis, which re-
quired a history of a preceding viral upper respiratory infection, the presence of wheezing
or crackles on chest auscultation, plus either an oxygen saturation of < 94% in room air
or RDAI score of >= 4
Exclusion criteria: previous episode of wheezing, chronic cardiopulmonary disease or
immunodeficiency, critical illness at presentation requiring admission to intensive care,
the use of nebulised HS within the previous 12 hours, or premature birth (gestational
age <= 34 weeks)
Interventions Test group: nebulised 3% hypertonic saline (4 ml)
Control group: nebulised 0.9% normal saline (4 ml)
The treatment was given every 2 hours for 3 doses, followed by every 4 hours for 5
doses, followed by every 6 hours until discharge. All inhaled therapies were delivered to
a settled infant from a standard oxygen-driven hospital nebuliser through a tight-fitting
face-mask, or head box, whichever was better tolerated by the infant
Outcomes Length of hospital stay
Treatments received during the study
Adverse events
Notes RSV positive: 62% in HS group; 75% in NS group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based randomisation program
Allocation concealment (selection bias) Low risk Sequentially numbered drug containers of
identical appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 patients from HS group and 3 from NS
group were withdrawn at parental request
because of perceived adverse effects of ther-
apy
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Kuzik 2007 (Continued)
Intention-to-treat analysis used
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Luo 2010
Methods Design: randomised, double-blind, parallel-group, controlled trial
Participants Setting: inpatient wards of a teaching hospital for children in China
Eligible: not stated
Randomised: 50 HS group; 43 NS group
Completed: 50 HS group; 43 NS group
Gender (male): 60.2%
Age: mean age 5.8 months, range 1 to 16.5 months
Inclusion criteria: infants with a diagnosis of mild to moderately severe bronchiolitis
Exclusion criteria: age > 24 months, previous episode of wheezing, chronic cardiac and
pulmonary disease, immunodeficiency, accompanying respiratory failure, requiring me-
chanical ventilation, inhaling the nebulised 3% hypertonic saline solution and salbuta-
mol 12 h before treatment, and premature infants born at less than 34 weeks gestation
Interventions Test group: nebulised 3% hypertonic saline (4 ml) plus 2.5 mg of salbutamol
Control group: nebulised 0.9% normal saline (4 ml) plus 2.5 mg of salbutamol
Patients in each group received 3 treatments every day, delivered at intervals of 8 h until
discharge using air-compressed nebulisers
Outcomes Length of hospital stay
Duration of symptoms and signs
Clinical score
Adverse events
Notes RSV positive: 70% in HS group; 69.7% in NS group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details were reported
Allocation concealment (selection bias) Low risk Sequentially numbered drug containers of
identical appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
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Luo 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised patients completed the trial
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Luo 2011
Methods Design: randomised, double-blind, parallel-group, controlled trial
Participants Setting: inpatient wards of a teaching hospital for children in China
Eligible: 135
Randomised: 64 HS group; 62 NS group
Completed: 57 HS group; 55 NS group
Gender (male): 56.3%
Age: mean age: 5.9 ± 4.1 months in HS group; 5.8 ± 4.3 months in NS group
Inclusion criteria: infants aged < 24 months with a first episode of wheezing, hospitalised
for treatment of moderate to severe bronchiolitis
Exclusion criteria: age > 24 months, previous episode of wheezing, chronic cardiac and
pulmonary disease, immunodeficiency, accompanying respiratory failure, requiring me-
chanical ventilation, inhaling the nebulised 3% HS solution 12 h before treatment, and
prematurity, with birth at < 34 weeks of gestation
Interventions Test group: nebulised 3% hypertonic saline (4 ml)
Control group: nebulised 0.9% normal saline (4 ml)
The treatment was given every 2 hours for 3 doses, followed by every 4 hours for 5 doses,
followed by every 6 hours until discharge. All inhaled treatments were delivered to infants
from standard air-compressed nebulisers (PARI Corporation, Starnford, Germany)
Outcomes Length of hospital stay
Duration of symptoms and signs
Clinical score
Adverse events
Notes RSV positive: 73.7% in HS group; 72.7% in NS group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based randomisation program
Allocation concealment (selection bias) Low risk Sequentially numbered, sealed, opaque en-
velopes
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Luo 2011 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk -
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Mandelberg 2003
Methods Design: randomised, double-blind, parallel-group, controlled trial
Participants Setting: inpatient ward, the Edith Wolfson Medical Center, Israel
Eligible: 61
Randomised: 31 (0.9% saline group); 30 (3% saline group)
Completed: 25 HS group; 27 NS group
Gender (male): 57.7%
Age: mean age 2.9 months, range 0.5 to 12 months
Inclusion criteria: infants with clinical presentation of viral bronchiolitis with tempera-
tures > 38 ºC that lead to hospitalisation
Exclusion criteria: cardiac disease, chronic respiratory disease, previouswheezing episode,
age > 12 months, oxygen saturation < 85% in room air, changes in consciousness and/
or progressive respiratory failure requiring mechanical ventilation
Interventions Test group: nebulised 3% saline solution (4 ml) plus 1.5 mg epinephrine
Control group: nebulised 0.9% saline solution (4 ml) plus 1.5 mg epinephrine
The treatment was given 3 times/day at intervals of 8 hours, until the patient was ready
for discharge. All inhaled treatments were delivered using a nebuliser (AeromistNebuliser
Set 61400; B&F Medical by Allied; Toledo, OH) connected to a source of pressurised
oxygen at a flow rate of 5 L/min
Outcomes Length of hospital stay
Change in clinical severity score
Others: pulse rate, saturation on room air, radiograph assessment score, number of add-
on treatments, adverse events
Notes RSV positive: 85% in HS group; 88% in NS group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation in blocks of 4, using an on-
line randomiser
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Mandelberg 2003 (Continued)
Allocation concealment (selection bias) Low risk Sequentially numbered drug containers of
identical appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 14 patients were withdrawn from the trial
(7 patients in each group discharged within
12 h after enrolment)
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Sarrell 2002
Methods Design: randomised, double-blind, parallel-group, controlled trial
Participants Setting: The Paediatrics and Adolescent Ambulatory Community Clinic of General
Health Services of Petach-Tikva, Israel
Eligible: not stated
Randomised: 70
Completed: 32 (0.9% saline group); 33 (3% saline group)
Gender (male): 59%
Age: mean age 12.5 months, range 3 to 24 months
Inclusion criteria: infants with clinical presentation of mild-to-moderate viral bronchi-
olitis
Exclusion criteria: cardiac disease, chronic respiratory disease, previouswheezing episode,
age >= 24 months, oxygen saturation < 96% on room air, and need for hospitalisation
Interventions Test group: nebulised 3% saline solution (2 ml) plus 5 mg (0.5 ml) terbutaline
Control group: nebulised 0.9% saline solution (2 ml) plus 5 mg (0.5 ml) terbutaline
The treatment was given 3 times/day at intervals of 8 hours for 5 days
Outcomes Change in clinical severity score
Hospitalisation rate
Others: radiograph assessment score, pulse rate, adverse events
Notes RSV positive: 82% in HS group; 78% in NS group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation in blocks of 4, using an on-
line randomiser
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Sarrell 2002 (Continued)
Allocation concealment (selection bias) Low risk Sequentially numbered drug containers of
identical appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5 patients were withdrawn, but the reasons
were not stated
Intention-to-treat analysis used
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Tal 2006
Methods Design: randomised, double-blind, parallel-group, controlled trial
Randomisation: randomisation in blocks of 4, using an online randomiser
Blinding: double-blind
Withdrawals/drop-outs: 2 patients from the 0.9% saline group were withdrawn, 1 be-
cause of clinical deterioration and another because of parental refusal. 1 patient from the
3% saline group was withdrawn because of protocol violation
Participants Setting: inpatient ward, the Wolfson Medical Center, Israel
Eligible: unclear
Randomised: 22 (0.9% saline group); 22 (3% saline group)
Completed: 20 (0.9% saline group); 21 (3% saline group)
Gender (male): 56.1%
Age: mean age 2.6 months, range 1 to 5 months
Inclusion criteria: infants with clinical presentation of viral bronchiolitis that led to
hospitalisation
Exclusion criteria: cardiac disease, chronic respiratory disease, previouswheezing episode,
age > 12 months, oxygen saturation < 85% on room air, obtunded consciousness and/
or progressive respiratory failure requiring mechanical ventilation
Interventions Test group: nebulised 3% saline solution (4 ml) plus 1.5 mg epinephrine
Control group: nebulised 0.9% saline solution (4 ml) plus 1.5 mg epinephrine. The
treatment was given 3 times/day at intervals of 8 hours, until the patient was ready for
discharge. All inhaled treatments were delivered using an ultrasonic nebuliser (Omron
UI, OMRONMatsusaka Co. Ltd., Japan)
Outcomes Length of hospital stay
Change in clinical severity score
Notes RSV positive: 86% in HS group; 75% in NS group
Risk of bias
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Tal 2006 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation in blocks of 4, using an on-
line randomiser
Allocation concealment (selection bias) Low risk Sequentially numbered drug containers of
identical appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 patients from the 0.9% saline group were
withdrawn, 1 because of clinical deterio-
ration and another because of parental re-
fusal. 1 patient from the 3% saline group
was withdrawn because of protocol viola-
tion
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
CS = clinical severity
h = hours
HS = hypertonic saline
ICU = intensive care unit
NS = normal saline
RDAI = Respiratory Distress Assessment Instrument
RSV = respiratory syncytial virus
SaO2 = oxygen saturation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Amirav 2005 Study of drug delivery (hood versus face-mask)
Guomo 2007 Abstract only
Kuzik 2010 Inclusion of patients with previous history of wheezing
Tribastone 2003 Summary of Sarrell 2002
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D A T A A N D A N A L Y S E S
Comparison 1. Hypertonic saline versus normal saline (0.9%)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Length of hospital stay (days) 6 500 Mean Difference (IV, Random, 95% CI) -1.15 [-1.49, -0.82]
2 Rate of hospitalisation 4 380 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.37, 1.07]
3 Clinical severity score
(post-treatment) at day 1
7 640 Mean Difference (IV, Random, 95% CI) -0.88 [-1.36, -0.39]
3.1 Outpatients 1 65 Mean Difference (IV, Random, 95% CI) -1.28 [-1.92, -0.64]
3.2 Emergency department
patients
1 171 Mean Difference (IV, Random, 95% CI) -0.09 [-0.51, 0.33]
3.3 Inpatients 5 404 Mean Difference (IV, Random, 95% CI) -0.99 [-1.48, -0.50]
4 Clinical severity score
(post-treatment) at day 2
7 636 Mean Difference (IV, Random, 95% CI) -1.32 [-2.00, -0.64]
4.1 Outpatients 1 65 Mean Difference (IV, Random, 95% CI) 0.00 [-2.93, -1.07]
4.2 Emergency department
patients
1 171 Mean Difference (IV, Random, 95% CI) -0.27 [-0.63, 0.09]
4.3 Inpatients 5 400 Mean Difference (IV, Random, 95% CI) -1.45 [-2.06, -0.85]
5 Clinical severity score
(post-treatment) at day 3
6 439 Mean Difference (IV, Random, 95% CI) -1.51 [-1.88, -1.14]
5.1 Outpatients 1 65 Mean Difference (IV, Random, 95% CI) -2.64 [-3.85, -1.43]
5.2 Inpatients 5 374 Mean Difference (IV, Random, 95% CI) -1.44 [-1.78, -1.10]
6 Rate of readmission 3 366 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.62, 1.76]
7 Time for resolution of
symptoms/signs
2 615 Mean Difference (IV, Random, 95% CI) -1.19 [-1.54, -0.84]
7.1 Wheezing 2 205 Mean Difference (IV, Random, 95% CI) -1.16 [-1.43, -0.89]
7.2 Cough 2 205 Mean Difference (IV, Random, 95% CI) -1.01 [-1.35, -0.66]
7.3 Pulmonary moist crackles 2 205 Mean Difference (IV, Random, 95% CI) -1.30 [-2.28, -0.32]
8 Radiological assessment score 2 117 Mean Difference (IV, Random, 95% CI) -0.08 [-0.90, 0.75]
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Analysis 1.1. Comparison 1 Hypertonic saline versus normal saline (0.9%), Outcome 1 Length of hospital
stay (days).
Review: Nebulised hypertonic saline solution for acute bronchiolitis in infants
Comparison: 1 Hypertonic saline versus normal saline (0.9%)
Outcome: 1 Length of hospital stay (days)
Study or subgroup Hypertonic saline 0.9% saline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mandelberg 2003 27 3 (1.2) 25 4 (1.9) 11.5 % -1.00 [ -1.87, -0.13 ]
Tal 2006 21 2.6 (1.4) 20 3.5 (1.7) 9.9 % -0.90 [ -1.86, 0.06 ]
Kuzik 2007 47 2.6 (1.9) 49 3.5 (2.9) 9.5 % -0.90 [ -1.88, 0.08 ]
Luo 2010 50 6 (1.2) 43 7.4 (1.5) 21.6 % -1.40 [ -1.96, -0.84 ]
Luo 2011 57 4.8 (1.2) 55 6.4 (1.4) 25.6 % -1.60 [ -2.08, -1.12 ]
Giudice 2012 52 4.9 (1.3) 54 5.6 (1.6) 21.8 % -0.70 [ -1.25, -0.15 ]
Total (95% CI) 254 246 100.0 % -1.15 [ -1.49, -0.82 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 7.18, df = 5 (P = 0.21); I2 =30%
Test for overall effect: Z = 6.83 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 1.2. Comparison 1 Hypertonic saline versus normal saline (0.9%), Outcome 2 Rate of
hospitalisation.
Review: Nebulised hypertonic saline solution for acute bronchiolitis in infants
Comparison: 1 Hypertonic saline versus normal saline (0.9%)
Outcome: 2 Rate of hospitalisation
Study or subgroup Hypertonic saline 0.9% saline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sarrell 2002 2/33 3/32 9.3 % 0.65 [ 0.12, 3.62 ]
Grewal 2009 8/23 13/23 62.4 % 0.62 [ 0.32, 1.20 ]
Anil 2010 1/75 1/74 3.6 % 0.99 [ 0.06, 15.48 ]
Ipek 2011 5/60 8/60 24.6 % 0.63 [ 0.22, 1.80 ]
Total (95% CI) 191 189 100.0 % 0.63 [ 0.37, 1.07 ]
Total events: 16 (Hypertonic saline), 25 (0.9% saline)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.3. Comparison 1 Hypertonic saline versus normal saline (0.9%), Outcome 3 Clinical severity
score (post-treatment) at day 1.
Review: Nebulised hypertonic saline solution for acute bronchiolitis in infants
Comparison: 1 Hypertonic saline versus normal saline (0.9%)
Outcome: 3 Clinical severity score (post-treatment) at day 1
Study or subgroup Hypertonic saline 0.9% saline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Outpatients
Sarrell 2002 33 4.36 (1.05) 32 5.64 (1.54) 14.0 % -1.28 [ -1.92, -0.64 ]
Subtotal (95% CI) 33 32 14.0 % -1.28 [ -1.92, -0.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.90 (P = 0.000095)
2 Emergency department patients
Al-Ansari 2010 115 3.88 (1.13) 56 3.97 (1.4) 16.3 % -0.09 [ -0.51, 0.33 ]
Subtotal (95% CI) 115 56 16.3 % -0.09 [ -0.51, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
3 Inpatients
Mandelberg 2003 27 7.7 (1.54) 25 7.81 (1.49) 12.1 % -0.11 [ -0.93, 0.71 ]
Tal 2006 21 6.25 (1.1) 20 7 (1) 14.0 % -0.75 [ -1.39, -0.11 ]
Luo 2010 50 3.4 (1.2) 43 4.9 (1.7) 14.3 % -1.50 [ -2.11, -0.89 ]
Luo 2011 57 5.7 (1.5) 55 7.3 (1.7) 14.5 % -1.60 [ -2.19, -1.01 ]
Giudice 2012 52 8 (1.3) 54 8.8 (1.6) 14.9 % -0.80 [ -1.35, -0.25 ]
Subtotal (95% CI) 207 197 69.8 % -0.99 [ -1.48, -0.50 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 12.01, df = 4 (P = 0.02); I2 =67%
Test for overall effect: Z = 3.94 (P = 0.000081)
Total (95% CI) 355 285 100.0 % -0.88 [ -1.36, -0.39 ]
Heterogeneity: Tau2 = 0.33; Chi2 = 27.85, df = 6 (P = 0.00010); I2 =78%
Test for overall effect: Z = 3.56 (P = 0.00038)
Test for subgroup differences: Chi2 = 12.31, df = 2 (P = 0.00), I2 =84%
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Analysis 1.4. Comparison 1 Hypertonic saline versus normal saline (0.9%), Outcome 4 Clinical severity
score (post-treatment) at day 2.
Review: Nebulised hypertonic saline solution for acute bronchiolitis in infants
Comparison: 1 Hypertonic saline versus normal saline (0.9%)
Outcome: 4 Clinical severity score (post-treatment) at day 2
Study or subgroup Hypertonic saline 0.9% saline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Outpatients
Sarrell 2002 33 2.77 (1.4) 32 4.77 (2.31) 12.6 % -2.00 [ -2.93, -1.07 ]
Subtotal (95% CI) 33 32 12.6 % -2.00 [ -2.93, -1.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.21 (P = 0.000026)
2 Emergency department patients
Al-Ansari 2010 115 3.85 (1.16) 56 4.12 (1.11) 15.7 % -0.27 [ -0.63, 0.09 ]
Subtotal (95% CI) 115 56 15.7 % -0.27 [ -0.63, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
3 Inpatients
Mandelberg 2003 24 6.41 (1.4) 25 6.92 (1.62) 13.1 % -0.51 [ -1.36, 0.34 ]
Tal 2006 20 5.35 (1.3) 20 6.45 (1) 13.9 % -1.10 [ -1.82, -0.38 ]
Luo 2010 50 2.2 (1.1) 43 3.8 (1.5) 14.9 % -1.60 [ -2.14, -1.06 ]
Luo 2011 57 3.5 (1.1) 55 5.9 (1.5) 15.2 % -2.40 [ -2.89, -1.91 ]
Giudice 2012 52 6.8 (1.4) 54 8.2 (1.7) 14.6 % -1.40 [ -1.99, -0.81 ]
Subtotal (95% CI) 203 197 71.7 % -1.45 [ -2.06, -0.85 ]
Heterogeneity: Tau2 = 0.36; Chi2 = 18.94, df = 4 (P = 0.00081); I2 =79%
Test for overall effect: Z = 4.74 (P < 0.00001)
Total (95% CI) 351 285 100.0 % -1.32 [ -2.00, -0.64 ]
Heterogeneity: Tau2 = 0.73; Chi2 = 56.79, df = 6 (P<0.00001); I2 =89%
Test for overall effect: Z = 3.81 (P = 0.00014)
Test for subgroup differences: Chi2 = 18.98, df = 2 (P = 0.00), I2 =89%
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Analysis 1.5. Comparison 1 Hypertonic saline versus normal saline (0.9%), Outcome 5 Clinical severity
score (post-treatment) at day 3.
Review: Nebulised hypertonic saline solution for acute bronchiolitis in infants
Comparison: 1 Hypertonic saline versus normal saline (0.9%)
Outcome: 5 Clinical severity score (post-treatment) at day 3
Study or subgroup Hypertonic saline 0.9% saline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Outpatients
Sarrell 2002 33 1.77 (2.4) 32 4.41 (2.57) 7.4 % -2.64 [ -3.85, -1.43 ]
Subtotal (95% CI) 33 32 7.4 % -2.64 [ -3.85, -1.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.28 (P = 0.000019)
2 Inpatients
Mandelberg 2003 21 5.81 (1.68) 23 6.08 (2.03) 8.6 % -0.27 [ -1.37, 0.83 ]
Tal 2006 13 4.7 (1.5) 14 5.72 (1) 10.2 % -1.02 [ -1.99, -0.05 ]
Luo 2010 45 1.5 (0.5) 40 2.9 (0.7) 29.4 % -1.40 [ -1.66, -1.14 ]
Luo 2011 57 2.4 (0.9) 55 4.1 (1.1) 25.5 % -1.70 [ -2.07, -1.33 ]
Giudice 2012 52 5.8 (1.4) 54 7.6 (1.6) 18.9 % -1.80 [ -2.37, -1.23 ]
Subtotal (95% CI) 188 186 92.6 % -1.44 [ -1.78, -1.10 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 8.43, df = 4 (P = 0.08); I2 =53%
Test for overall effect: Z = 8.26 (P < 0.00001)
Total (95% CI) 221 218 100.0 % -1.51 [ -1.88, -1.14 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 11.90, df = 5 (P = 0.04); I2 =58%
Test for overall effect: Z = 7.98 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.51, df = 1 (P = 0.06), I2 =72%
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Analysis 1.6. Comparison 1 Hypertonic saline versus normal saline (0.9%), Outcome 6 Rate of readmission.
Review: Nebulised hypertonic saline solution for acute bronchiolitis in infants
Comparison: 1 Hypertonic saline versus normal saline (0.9%)
Outcome: 6 Rate of readmission
Study or subgroup Hypertonic saline 0.9% saline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Al-Ansari 2010 18/115 7/56 40.7 % 1.25 [ 0.56, 2.82 ]
Anil 2010 11/75 11/74 45.2 % 0.99 [ 0.46, 2.13 ]
Grewal 2009 3/23 4/23 14.1 % 0.75 [ 0.19, 2.98 ]
Total (95% CI) 213 153 100.0 % 1.05 [ 0.62, 1.76 ]
Total events: 32 (Hypertonic saline), 22 (0.9% saline)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Hypertonic saline versus normal saline (0.9%), Outcome 7 Time for resolution
of symptoms/signs.
Review: Nebulised hypertonic saline solution for acute bronchiolitis in infants
Comparison: 1 Hypertonic saline versus normal saline (0.9%)
Outcome: 7 Time for resolution of symptoms/signs
Study or subgroup Hypertonic saline 0.9% saline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Wheezing
Luo 2010 50 2.7 (0.9) 43 3.8 (1.1) 18.1 % -1.10 [ -1.51, -0.69 ]
Luo 2011 57 3.6 (0.9) 55 4.8 (1) 19.4 % -1.20 [ -1.55, -0.85 ]
Subtotal (95% CI) 107 98 37.4 % -1.16 [ -1.43, -0.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 8.46 (P < 0.00001)
2 Cough
Luo 2010 50 5.3 (0.8) 43 6.3 (0.9) 19.4 % -1.00 [ -1.35, -0.65 ]
Luo 2011 57 4.3 (7) 55 5.5 (0.9) 3.2 % -1.20 [ -3.03, 0.63 ]
Subtotal (95% CI) 107 98 22.6 % -1.01 [ -1.35, -0.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 5.76 (P < 0.00001)
3 Pulmonary moist crackles
Luo 2010 50 5.4 (0.8) 43 6.2 (0.9) 19.4 % -0.80 [ -1.15, -0.45 ]
Luo 2011 57 4.4 (0.9) 55 6.2 (0.7) 20.5 % -1.80 [ -2.10, -1.50 ]
Subtotal (95% CI) 107 98 40.0 % -1.30 [ -2.28, -0.32 ]
Heterogeneity: Tau2 = 0.47; Chi2 = 18.26, df = 1 (P = 0.00002); I2 =95%
Test for overall effect: Z = 2.61 (P = 0.0091)
Total (95% CI) 321 294 100.0 % -1.19 [ -1.54, -0.84 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 21.98, df = 5 (P = 0.00053); I2 =77%
Test for overall effect: Z = 6.65 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.62, df = 2 (P = 0.73), I2 =0.0%
-4 -2 0 2 4
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Analysis 1.8. Comparison 1 Hypertonic saline versus normal saline (0.9%), Outcome 8 Radiological
assessment score.
Review: Nebulised hypertonic saline solution for acute bronchiolitis in infants
Comparison: 1 Hypertonic saline versus normal saline (0.9%)
Outcome: 8 Radiological assessment score
Study or subgroup Hypertonic saline 0.9% saline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mandelberg 2003 27 3.38 (2.28) 25 3.43 (2.35) 43.0 % -0.05 [ -1.31, 1.21 ]
Sarrell 2002 33 1.5 (2.2) 32 1.6 (2.3) 57.0 % -0.10 [ -1.19, 0.99 ]
Total (95% CI) 60 57 100.0 % -0.08 [ -0.90, 0.75 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours hypertonic saline Favours 0.9% saline
A D D I T I O N A L T A B L E S
Table 1. Treatment regimens of nebulised hypertonic saline
Study ID Concentration of
saline
Volume of saline Addition of bron-
chodilator
Interval of admin-
istration
Treatment duration
Outpatient trial
Sarrell 2002 3% 2 ml Terbutaline 5 mg Every 8 hours 5 days
Emergency -based
trial
Al-Ansari 2010 3%, 5% 5 ml Epinephrine 1.5 ml Every 4 hours Until discharge
Anil 2010 3% 4 ml Epinephrine 1.5 ml
or salbutamol 2.5
mg
Every 30 minutes Until 2 doses had
been administrated
Grewal 2009 3% 2.5 ml 2.25% racaemic
epinephrine 0.5 ml
If needed, the second
dose was given dur-
ing the 120-minute
study period
Up to 2 doses
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Table 1. Treatment regimens of nebulised hypertonic saline (Continued)
Ipek 2011 3% 4 ml Salbutamol 0.15
mg/kg
Every 20 minutes Until 3 doses had
been administrated
Inpatient trial
Giudice 2012 3% ? ml Epinephrine 1.5 mg Every 6 hours Until discharge
Kuzik 2007 3% 4 ml Albuterol was added
in 37% of the treat-
ments and racaemic
epinephrine
was added in 23% of
the treatments by at-
tending physicians
Every 2 hours for
3 doses, followed by
every 4 hours for 5
doses, and then every
6 hours
Until discharge
Luo 2010 3% 4 ml Salbutamol 2.5 mg Every 8 hours Until discharge
Luo 2011 4 ml None Every 2 hours for
3 doses, followed by
every 4 hours for 5
doses, and then every
6 hours
Until discharge
Mandelberg 2003 3% 4 ml Epinephrine 1.5 mg Every 8 hours Until discharge
Tal 2006 3% 4 ml Epinephrine 1.5 mg Every 8 hours Until discharge
A P P E N D I C E S
Appendix 1. Previous search
For the 2010 update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 2),
which contains the Cochrane Acute Respiratory Infections Group Specialised Register, OLDMEDLINE (1951 to 1965), MEDLINE
(1966 to May Week 4, 2010), EMBASE (1974 to June 2010) and LILACS (1985 to June 2010).
For the original search we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007,
Issue 4), which contains the Cochrane Acute Respiratory Infections Group Specialised Register, OLDMEDLINE (1951 to 1965),
MEDLINE (1966 to November 2007), EMBASE (1974 to November 2007) and LILACS (November 2007).
The following search terms were combined with the highly sensitive search strategy as recommended by The Cochrane Collaboration
(Dickersin 1994) to search MEDLINE. These terms were adapted to search CENTRAL, EMBASE and LILACS as required.
MEDLINE (OVID)
1 exp Bronchiolitis/
2 bronchiolit$.mp.
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3 exp Respiratory Syncytial Viruses/
4 exp Respiratory Syncytial Virus Infections/
5 (respiratory syncytial vir$ or RSV).mp.
6 exp Parainfluenza Virus 1, Human/
7 exp Parainfluenza Virus 2, Human/
8 exp Parainfluenza Virus 3, Human/
9 exp Respirovirus Infections/
10 exp Adenoviridae Infections/
11 exp Influenza, Human/
12 (parainfluenza or adenovirus$ or influenza).mp.
13 or/1-12
14 exp Saline Solution, Hypertonic/
15 hypertonic saline.mp.
16 exp Sodium Chloride/
17 saline.mp.
18 or/14-17
19 exp “Nebulizers and Vaporizers”/
20 (nebulis$ or nebuliz$).mp.
21 exp Administration, Inhalation/
22 inhal$.mp.
23 exp Aerosols/
24 aerosol$.mp.
25 or/19-24
26 13 and 18 and 25
27 from 26 keep 1-79
There were no language or publication restrictions.
Appendix 2. Embase.com search strategy
24. #12 AND #16 AND #23
23. #17 OR #18 OR #19 OR #20 OR #21 OR #22
22. aerosol*:ab,ti
21. ’aerosol’/de
20. inhal*:ab,ti
19. ’inhalational drug administration’/de
18. nebuli*:ab,ti OR vapour*:ab,ti OR vapour*:ab,ti OR atomi*:ab,ti
17. ’nebulizer’/exp
16. #13 OR #14 OR #15
15. ’sodium chloride’:ab,ti OR saline:ab,ti
14. (hypertonic NEAR/3 (saline OR solution*)):ab,ti
13. ’hypertonic solution’/de OR ’sodium chloride’/de
12. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11
11. parainfluenza*:ab,ti OR respirovirus*:ab,ti OR adenovirus*:ab,ti OR rhinovirus*:ab,ti OR
influenza*:ab,ti
10. ’influenza virus’/de OR ’influenza virus a’/exp OR ’influenza virus b’/de OR ’influenza’/exp
9. ’rhinovirus infection’/de
8. ’human adenovirus infection’/de
7. ’respirovirus infection’/de
6. ’parainfluenza virus 1’/de OR ’parainfluenza virus 2’/de OR ’parainfluenza virus 3’/de
5. ’respiratory syncytial virus’:ab,ti OR ’respiratory syncytial viruses’:ab,ti OR rsv:ab,ti
4. ’respiratory syncytial virus infection’/de
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3. ’respiratory syncytial pneumovirus’/de
2. bronchiolit*:ab,ti
1. ’bronchiolitis’/exp
Appendix 3. LILACS search strategy
> Search > (MH:Bronchiolitis OR bronchiolit$ OR Bronquiolitis OR Bronquiolite OR MH:C08.127.446.135$ OR MH:
C08.381.495.146.135$ ORMH:C08.730.099.135$ OR wheez$ ORMH:“Respiratory Syncytial Viruses” OR “Virus Sincitiales Res-
piratorios” OR “Vírus Sinciciais Respiratórios” OR “Respiratory Syncytial Virus, Human” OR “Respiratory Syncytial Virus Infections”
OR “Infecciones por Virus Sincitial Respiratorio” OR “Infecções por Vírus Respiratório Sincicial” OR rsv “respiratory syncytial virus”
OR “respiratory syncytial virus infection” OR “respiratory syncytial virus infections”) AND (MH:“Saline Solution, Hypertonic” OR
“Solución Salina Hipertónica” OR “Solução Salina Hipertônica” OR “Hypertonic Saline Solution” OR “Solución Hipertónica de
Cloruro de Sodio” OR “Solução Salina Hipertônica” OR “Solução Hipertônica de Cloreto de Sódio” OR MH:“Sodium Chloride”
OR “sodium chloride” OR “Cloruro de Sodio” OR “Cloreto de Sódio” OR salin$) AND (MH:“Nebulizers and Vaporizers” ORMH:
E07.605$ OR atomi$ OR inhal$ OR vapor$ OR vapour$ OR nebuli$ OR Inala$ OR MH:Aerosols OR aerosol$ OR Aerossóis OR
MH:“Administration, Inhalation” OR “Administración por Inhalación” OR “Administração por Inalação”)
Appendix 4. CINAHL (Ebsco) search strategy
S22 S10 and S15 and S21
S21 S16 or S17 or S18 or S19 or S20
S20 TI (inhal* or aerosol*) OR AB (inhal* or aerosol*)
S19 (MH “Aerosols”)
S18 (MH “Administration, Inhalation”)
S17 TI (nebuli* or vapor* or vapour* or atomi*) OR AB (nebuli* or vapor* or vapour* or atomi*)
S16 (MH “Nebulizers and Vaporizers”)
S15 S11 or S12 or S13 or S14
S14 TI (sodium chloride or saline) OR AB (sodium chloride or saline)
S13 (MH “Sodium Chloride”)
S12 TI (hypertonic N3 (salin* or solut*)) OR AB (hypertonic N3 (salin* or solut*))
S11 (MH “Saline Solution, Hypertonic”)
S10 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9
S9 TI (influenza* or flu) OR AB (influenza* or flu)
S8 (MH “Influenzavirus A+”) OR (MH “Influenzavirus B+”)
S7 (MH “Influenza”) OR (MH “Influenza, Human”) OR (MH “Influenza A H5N1”) OR (MH “Influenza, Pandemic (H1N1) 2009”)
OR (MH “Influenza, Seasonal”)
S6 TI (parainfluenza* or respirovirus* or adenovirus* or rhinovirus*) OR AB (parainfluenza* or respirovirus* or adenovirus* or
rhinovirus*)
S5 TI (respiratory syncytial virus* or rsv) OR AB (respiratory syncytial virus* or rsv)
S4 (MH “Respiratory Syncytial Virus Infections”)
S3 (MH “Respiratory Syncytial Viruses”)
S2 TI (bronchiolit* or wheez*) OR AB (bronchiolit* or wheez*)
S1 (MH “Bronchiolitis+”)
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Appendix 5. Web of Science (Thomson Reuters) search strategy
# 3 93 #2 AND #1
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
# 2 1,322,438 Topic=(random* or placebo* or ((single or double) NEAR/1 blind*) or allocat* or (clinical NEAR/1 trial*)) OR
Title=(trial)
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
# 1 173 Topic=(bronchiolit* or wheez* or “respiratory syncytial virus” or “respiratory syncytial viruses” or rsv or parain-
fluenza* or “respirovirus infection” or “respirovirus infections” or rhinovirus* or adenovirus* or influenza*) AND
Topic=((hypertonic NEAR/3 (salin* or solut*)) or “sodium chloride” or saline) AND Topic=(nebuli* or vapor*
or vapour* or atomi* or inhal* or aerosol*)
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
WH A T ’ S N E W
Last assessed as up-to-date: 8 May 2013.
Date Event Description
8 May 2013 New search has been performed Searches conducted. We included four new trials (Al-
Ansari 2010; Giudice 2012; Ipek 2011; Luo 2011) and
performed new analyses. Our conclusions remain un-
changed
8 May 2013 New citation required but conclusions have not changed Our conclusions remain unchanged.
H I S T O R Y
Protocol first published: Issue 2, 2007
Review first published: Issue 4, 2008
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Date Event Description
7 June 2010 New search has been performed Searches conducted. We included three new trials (Anil 2010; Grewal 2009;
Luo 2010) and conductednewanalyses. The conclusions remain unchanged
13 May 2009 Amended No changes - republished to fix technical problem.
18 February 2008 Amended Converted to new review format.
13 November 2007 New search has been performed Searches conducted.
C O N T R I B U T I O N S O F A U T H O R S
Linjie Zhang (LZ) conceived the idea and wrote the draft protocol, the primary review and updated the review.
LZ and Raúl A Mendoza-Sassi (RAM) were responsible for study selection, quality assessment, data collection and data analysis.
RAM, Claire Wainwright (CW) and Terry P Klassen (TPK) provided input for writing the protocol and review.
The final version of the updated review was approved by all authors.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Faculty of Medicine, Universidade Federal do Rio Grande, Brazil.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Given the very limited number of studies that were identified initially, we added the comparison of nebulised hypertonic saline alone
versus nebulised 0.9% saline. We also clarified the population according to the age and changed the title to specify infants.
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N O T E S
We performed post hoc meta-regression in the updated review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Bronchiolitis, Viral [∗therapy]; Bronchodilator Agents [administration & dosage]; Nebulizers and Vaporizers; Random-
ized Controlled Trials as Topic; Saline Solution, Hypertonic [∗administration & dosage]
MeSH check words
Humans; Infant
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